U.S. appeals court judges appear divided over whether to allow a research center affiliated with MIT and Harvard to keep patents potentially worth billions of dollars on a groundbreaking gene editing technology known as CRISPR.

 

Patents on the technology that could revolutionize treatment of genetic diseases and crop engineering are held by the Broad Institute, which was challenged in court by a rival team associated with the University of California at Berkeley and University of Vienna in Austria.

 

Their lawyers argued at a hearing on Monday in the U.S. Court of Appeals for the Federal Circuit in Washington that the Broad Institute’s contributions were obvious and that an administrative court decision allowing Broad’s patents to stand should be reversed.

 

Click Here to read more.